Ptc Therapeutics, INC Form 4 insider transactions

Matthew B. Klein, CHIEF EXECUTIVE OFFICER and a Director of Ptc Therapeutics, Inc., sold 10,292 shares of common stock on August 4, 2026 for $68.57 per share.

Hege Elisabeth Sollie-Zetlmayer, a Director of Ptc Therapeutics, Inc., reported multiple transactions in common stock on July 28, 2026.

Pierre Gravier, CHIEF FINANCIAL OFFICER of Ptc Therapeutics, Inc., sold 3,494 shares of common stock on July 14, 2026 for $80.35 per share.

Mary L. Smith, a Director of Ptc Therapeutics, Inc., sold 15,834 shares of common stock on July 9, 2026 for $90.00 per share.

Neil Gregory Almstead, CHIEF TECHNICAL OPS OFFICER of Ptc Therapeutics, Inc., sold 2,464 shares of common stock on July 9, 2026 for $90.25 per share.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, Inc., reported transactions involving the sale of common stock under a pre-arranged trading plan.

Neil Gregory Almstead, Chief Technical Ops Officer at PTC Therapeutics, reported a series of stock transactions on July 6th and 7th, 2026, involving both acquisitions and dispositions of common stock and stock options.

Neil Gregory Almstead, Chief Technical Ops Officer at PTC Therapeutics, reported transactions involving the purchase and sale of company stock under a Rule 10b5-1 trading plan.

Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, reported transactions involving the purchase and sale of company common stock under a Rule 10b5-1 trading plan.

Neil Gregory Almstead, Chief Technical Ops Officer at PTC Therapeutics, reported transactions involving the sale of company stock and the acquisition of stock options.

Chief Business Officer Eric Pauwels sold 21,277 shares of PTC Therapeutics common stock under a pre-arranged Rule 10b5-1 trading plan.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, Inc., reported transactions involving the sale of common stock and the acquisition of stock options.

CEO Matthew Klein acquired 12,500 shares via performance-based unit vesting and sold 12,572 shares to cover tax obligations.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, exercised stock options and sold shares under a Rule 10b5-1 plan.

PTC Therapeutics CEO Matthew B. Klein sold 2,850 shares of common stock to satisfy tax obligations related to RSU vesting.

Mark Elliott Boulding, Executive VP and CLO of PTC Therapeutics, Inc., reported transactions involving the sale of common stock and the acquisition of stock options under a pre-arranged trading plan.

Scott Golden Lee, EVP & Chief Medical Officer at PTC Therapeutics, reported a transaction involving the sale of common stock.

Neil Gregory Almstead, Chief Technical Operations Officer at PTC Therapeutics, reported the sale of common stock under a pre-arranged trading plan.

PTC Therapeutics Director Jessica Caroline Chutter was granted restricted stock units and stock options as part of her compensation.

PTC Therapeutics CEO Matthew B. Klein reported the acquisition of 12,500 common shares from RSU vesting and the sale of 2,662 shares to cover tax obligations.

PTC Therapeutics Director Stephanie Okey executed pre-planned transactions, exercising stock options and subsequently selling common stock.

A PTC Therapeutics executive has filed a Form 4 disclosing planned future sales of common stock under a Rule 10b5-1 trading plan.

PTC Therapeutics' SVP, Chief Accounting Officer, Christine Marie Utter, sold 2,494 shares of common stock to cover tax obligations related to RSU vesting.

PTC Therapeutics' Chief Financial Officer, Pierre Gravier, sold 2,992 shares of common stock to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics' Chief Business Officer, Eric Pauwels, filed a Form 4 detailing a future 'sell to cover' transaction for tax withholding related to RSU vesting.

PTC Therapeutics CEO Matthew B. Klein sold 7,371 shares of common stock to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics' EVP & Chief Medical Officer, Lee Scott Golden, sold 2,484 shares of common stock to cover tax withholding obligations related to RSU vesting.

PTC Therapeutics' Chief Technical Operations Officer, Neil Gregory Almstead, sold shares to cover tax obligations related to RSU vesting.

PTC Therapeutics' Executive VP and CLO, Mark Elliott Boulding, exercised stock options and subsequently sold a portion of his common stock holdings, primarily to cover tax obligations.

PTC Therapeutics' SVP, Chief Accounting Officer, Christine Marie Utter, sold 1,034 shares of common stock to cover tax obligations related to RSU vesting.